Transcription of the ERBB2 oncogene is repressed by oestrogen in human breast cancer cells. We show that a 218 bp fragment of the human ERBB2 gene promoter is responsive to oestrogen in transient transfection in ZR75.1 and SKBR.3 cells when the oestrogen receptor is expressed. Deletion analysis of this fragment shows that a sequence located at the 5' end, which is known to mediate ERBB2 overexpression in breast cancer, is also responsible for the oestrogen response. This sequence binds AP-2 transcription factors and appears functionally identical to an element of the oestrogen-dependent enhancer described in the ®rst intron of human ERBB2. We observed that oestrogen treatment down-regulates expression of AP-2 proteins but does not aect the DNA binding activity of AP-2. Constitutive expression of AP2b or AP-2g, but not AP-2a, abrogates the estrogenic repression. Our results demonstrate that AP-2 transcription factors are implicated in the oestrogenic regulation of ERBB2 gene expression and suggest a complex interplay involving the dierent AP-2 isoforms and other unidenti®ed factors. Oncogene (2000) 19, 280 ± 288.
Introduction
The ERBB2 gene, encoding for a 185 kDa transmembrane receptor tyrosine kinase, is an important human oncogene, activated by ampli®cation/overexpression in a number of human adenocarcinomas, including ovary, lung and breast, where it represents a strong prognostic factor (for review, see Hynes, 1993; Dougall et al., 1994) . In conjunction with the structurally similar EGFR, ErbB3 and ErbB4, ErbB2 composes a network of homo-and heterodimeric receptors showing hierarchical anities for a plethora of dierent ligands, including EGF, TGFa, betacellulin and neuregulins (for review, see Tzahar and Yarden, 1998) . Since signal transduction is particular to each ErbB protein, altered expression of ErbB2 may subvert the cellular response to speci®c ligands, leading to misinterpretation of autocrine and paracrine signals. Experimental data con®rm that, in vitro, ERBB2 transforming activity in both rodent ®broblasts and breast epithelial cell lines is linked to its level of expression, suggesting that the control of ERBB2 expression is critical in tumorigenesis.
Overexpression of ERBB2 in breast cancer is driven by AP-2 transcription factors, which recognize a promoter sequence 218 bp upstream from the major transcriptional starting site (Hollywood and Hurst, 1993; Bosher et al., 1995) . The involvement of three human genes, encoding for extremely conserved AP-2 proteins (AP-2a, AP-2b and AP-2g), in breast cancer has recently been addressed (Bosher et al., 1996; Turner et al., 1998) .
There is an inverse correlation between ERBB2 and oestrogen receptor (ER) expression in breast cancer. Mechanisms of reciprocal repression have been identi®ed: ®rst, the signaling pathway activated by the ErbB2 receptor permanently down-regulates ER expression (Pietras et al., 1995) . Second, we and others have shown that oestrogen-activated ER represses ERBB2 expression in vitro and in vivo (Dati et al., 1990; Read et al., 1990; Warri et al., 1991; Russel and Hung, 1992; Antoniotti et al., 1994; Bates and Hurst, 1997a) . Antioestrogens such as Tamoxifen and ICI 182,780 counteract the eect of oestrogen on ERBB2, i.e. they increase the expression of ERBB2 (Warri et al., 1991; Antoniotti et al., 1992) . This may represent an undesirable side eect of these drugs in breast cancer treatment (Borg et al., 1994) and understanding how oestrogen acts on ERBB2 may lead to eventual separation of antioestrogenic eect from stimulation of ERBB2, hence allowing the development of more eective drugs.
Oestrogen downregulates ERBB2 mostly, if not solely, by transcriptional repression, as demonstrated by run-on analysis Bates and Hurst, 1997a) and, when sucient ER is present, reduces the activity of transiently as well as stably transfected ERBB2 promoter-CAT constructs (Russel and Hung, 1992; Antoniotti et al., 1994; Taverna et al., 1994) .
The 5'-regulatory regions of the human, rat and mouse ERBB2 genes contain several response elements for transcription factors and oncogenes (reviewed in Bates and Hurst, 1997b) . No steroid response element was found, but the oestrogen-responsive region was restricted to a 140 bp region of the rat NEU gene promoter (Russel and Hung, 1992) .
More recently, an oestrogen-responsive enhancer was identi®ed in the ®rst intron of the human ERBB2 gene, which is capable of mediating oestrogen-dependent repression of transcription when cloned in proximity of the ERBB2 promoter (Bates and Hurst, 1997a) .
Detailed inspection of the enhancer sequence revealed a number of similarities with the promoter itself. This prompted us to further examine and localize the sequences that mediate a negative response to oestrogen within the ERBB2 promoter.
Our results show that the AP-2 element 218 bp upstream from the major transcriptional starting site, previously recognized as essential for ERBB2 overexpression in breast cancer, is required for repression by oestrogen-activated ER in breast cancer cells. This element binds AP2 in vitro and is biochemically indistinguishable from a footprinted sequence of the intronic enhancer (FPC), thus indicating that AP-2 factors are involved in the regulation of ERBB2 transcription by oestrogen.
Results
Localization of the oestrogen-dependent negative element in the human ERBB2 promoter Oestrogenic repression of ERBB2 promoter-CAT reporter constructs in ZR75.1 human breast cancer cells, which express endogenous ER (ER+), requires co-transfection of an ER-expressing vector .
Optimized transfection conditions are suboptimal for revealing oestrogenic eects on ERBB2 by the endogenous ER. In fact, to show full regulation of ERBB2, cells require several days in steroid-depleted medium (SM) to up-regulate ER, followed by 3 ± 6 days of treatment with oestrogen (Dati et al., 1990; Antoniotti et al., 1994) whereas, for transfection, cells are cultured in SM for 24 h and treated with oestrogen for only 32 h. In order to evaluate the need for ER cotransfection, the eect of treatment with 10 nM 17b-oestradiol on the activity of the pE2P.Pp.CAT reporter plasmid was compared in both ZR75.1 (ER+) and SKBR.3 (ER7) cells, with and without cotransfection of the ER expression vector pHEG0. pE2P.Pp.CAT contains sequences from 7397 to 7178, i.e. the major transcriptional starting site of the human ERBB2 gene (ATG is set as +1) (Hudson et al., 1990) . To exclude that results were due to quenching of trans-acting factors by sequences present in pHEG0, corresponding amounts of the parental vector pSG5 were transfected in controls. Results of duplicate transfections demonstrate that in ZR75.1 cells a repressive eect of oestrogen is mediated by the endogenous ER (720%), rising to 760% when ER was co-transfected ( Figure 1a) . In SKBR.3 cells, which do not express endogenous ER (ER7), there is an absolute need for ER co-transfection, that results in a very strong repression of pE2P.Pp.CAT activity (790%) ( Figure  1b) . Dependence on co-transfected ER was also seen using the pVit2-ERE.CAT plasmid, which contains three copies of the vitellogenin A2 gene oestrogen response element upstream of a TK basal promoter (Druege et al., 1986) . Induction of pVitA2-ERE.CAT by oestradiol was increased (3.2-fold vs 2.4-fold) in cells co-transfected with ER ( Figure 1c ), proving that in ZR75.1 cells the amount of endogenous ER is limiting.
These results con®rm that the most proximal 218 bp region of the ERBB2 promoter is negatively regulated by oestrogen and that co-transfection of ER is necessary to obtain a full response in both ER7 and ER+ cells.
In order to de®ne the sequences involved in this negative regulation, we produced a series of deletants from pE2P.Pp.CAT ( Figure 2 ) and tested their response to oestrogen in ZR75.1 cells. The rationale behind deletant design derives from the reported Figure 1 Repression of the ERBB2 promoter by oestrogen requires co-transfection of ER. 20 mg of pE2P.Pp.CAT reporter plasmid were transiently transfected in ZR75.1 (ER+) (a) and in SKBR3 (ER7) (b) human breast cancer cells, in the presence of 2 mg of the ER expression vector pHEG0 or its related void vector pSG5 and subjected to treatment with 10 nM 17b-oestradiol. CAT activities are corrected for b-galactosidase, and error bars indicate the standard deviation of duplicate plates. (c) Eect of oestrogen treatment on pVitA2-ERE.CAT activity in the presence or absence of ER co-transfection, in ZR75.1 cells AP-2 and ERBB2 repression by oestrogen V Perissi et al DNase I footprint map in ZR75.1 cells (Hollywood and Hurst, 1993) . Deletion of each FP sequence led to decreased basal activity, demonstrating that each of them contributes a positive and additive action on ERBB2 transcription. To determine individual response to oestrogen, six cell plates were set and transfected with a common precipitate. Three plates were successively treated with oestradiol and three left untreated. In each transfection session, the response of the parental plasmid pE2P.Pp.CAT was assayed in parallel, to provide an interassay normalization control. As shown in Figure 2 , all deletants lacking FP3 lost oestrogen responsiveness, whereas plasmid pDTha.CAT, which maintains FP3, but lacks the FP2 region, is equally repressed by oestrogen. Notably, removal of both FP2 and FP3 regions unmasks a positive eect on the most proximal part of the promoter.
These results strongly indicated that the element mediating oestrogen repression was close to the FP3 region, i.e. the one that drives ERBB2 overexpression in breast cancer (Hollywood and Hurst, 1993; Bosher et al., 1995) . To show whether the AP-2 binding site contained in FP3 was responsible for oestrogen eect, the pE2P.DPp.CAT mutant was produced, lacking the four central bases of the core binding element, shown to be necessary for AP-2 binding (Bosher et al., 1995) . As shown in Figure 2 , the activity of this mutant is not altered by oestrogen treatment.
Altogether, these results demonstrate for the ®rst time that an AP-2 site located at position 7397 in the human ERBB2 promoter is responsible for transcriptional repression by oestrogen.
In pE2P.Pp.CAT, the AP-2 site is¯anked in 5' by sequences of the plasmid vector, since it was constructed by cutting the gene at a PstI site embedded in the AP-2 site and cloning into the PstI site of pBLCAT3 . Although the core binding sequence, as de®ned by methylation interference, was not changed by this cloning procedure, and a similar construct was reported to behave identically to wild-type sequence (Hollywood and Hurst, 1993), we constructed and assayed a further plasmid, p(7413).CAT, containing all the nucleotides protected by FP3, i.e. 8 bp upstream and 12 bp downstream from the AP2 site. As shown in Figure  2 , p(7413).CAT was responsive to oestrogen, although to a lesser extent than pE2P.Pp.CAT. The basal activity of p(7413).CAT was also reduced, as compared to pE2P.Pp.CAT, whereas the residual activity of the two plasmids in the presence of oestrogens was almost identical. These results indicate that the AP-2 element mediates oestrogen eect in its natural context and that the strength of this element is possibly enhanced in the arti®cially constructed pE2P.Pp.CAT.
The FP3 sequence binds AP-2 and is equivalent to part of an oestrogen-responsive element of the ®rst intron of the human ERBB2 gene EMSA analysis was used to con®rm that the factor present in ZR75.1 cell nuclei binding the FP3 sequence was the AP-2 transcription factor.
Oligonucleotides representing the natural FP3 sequence (FP3wt), as well as the FP3 sequence contained in pE2P.Pp.CAT (FP3mod) ( Figure 3a) were synthesized, labeled and incubated with ZR75.1 nuclear extracts. Two retarded bands were observed ( Figure 3b ). Based on the complex formed by in vitro translated recombinant human AP-2a (lane a) and supershifting with an antiserum directed against the Cterminal domain of human AP-2 (lanes s, v), we conclude that the more slowly migrating band is a speci®c AP-2 complex, whereas the lower one represents an aspeci®c complex. As shown in Figure  3b , the complex formed with both probes was competed with roughly equivalent anity by a canonical human metallothionein-IIa AP-2 oligonucleotide (Williams and Tijan, 1991) (lanes g-i and n-p). At equimolecular concentration of the competitor, a visible reduction of the complex is seen and competition is almost complete at 106. Comparing the left and right sides of Figure 3b , it is evident that the FP3wt and FP3mod probes gave almost identical results, competed each other equally (lanes d-e, k-l) and were identically supershifted by the anti-AP-2 antiserum (lanes s, v).
These experiments con®rm that the factor binding to FP3 is AP-2 and that the modi®ed FP3 sequence present in pE2P.Pp.CAT shows unchanged speci®city and anity for ZR75.1 nuclear factors.
One of the four footprinted sequences described in the ERBB2 ®rst intron oestrogen-dependent enhancer (Bates and Hurst 1997a) , called FPC, is extremely similar to FP3 (Figure 3a) . The EMSA analysis shown in Figure 3c demonstrates that a FPC oligonucleotide forms a complex that is indistinguishable from FP3wt, is competed by canonical AP-2 and supershifted by the anti-AP2 antibody.
Since the most conserved sequence between FPC and FP3 is the central`core' (Figure 3a) , we competed the complexes with two mutants of FP3wt, the ®rst having the central`GC' mutated to`TT', the second carrying`lateral' mutations (the two`G'¯anking the PstI site converted to`T'). Both complexes were competed by the central but not at all by the lateral mutant (in Figure 3c , compare lanes c and i with lanes d and j). This con®rms that the 3' lateral nucleotides of Figure 2 Localization of the oestrogen-dependent negative element in the ERBB2 promoter. Map of the ERBB2 promoter deletants constructed and evaluation of their response to oestrogens in ZR75.1 cells. CAT activities were evaluated as described in Figure 1 . Basal activities, determined in dierent experiments, were normalized on the activity of pE2P.Pp.CAT. Bars represent the standard deviation of triplicate plates. FP1, FP2 and FP3 refer to the footprinted regions described in ZR75.1 cells (Hollywood and Hurst, 1993) . The arrow designates position of the major transcriptional starting site AP-2 and ERBB2 repression by oestrogen V Perissi et al the consensus site are fundamental for AP-2 binding (Williams and Tijan, 1991) and demonstrates the substantial equivalence of FP3 and FPC with ZR75.1 nuclear extracts.
In conclusion, these results demonstrate that the oestrogen-responsive element of the ERBB2 promoter and a sequence of the oestrogen-responsive intronic enhancer bind the same factor(s) in vitro.
Oestrogen downregulates AP-2 expression level but not its DNA binding activity
Since the eect of oestrogen on ERBB2 promoter is clearly the extinction of AP-2 transactivation through the FP3 site, we asked whether oestrogen could aect the expression or activity of AP-2. ZR75.1 cells were grown in oestrogenic (CM or SM+17b-oestradiol) Figure 3 Biochemical characterization of the oestrogen-dependent negative element in the ERBB2 promoter. (a) The sequence of the footprinted region around an AP-2 site at position 7397 in the ERBB2 promoter (FP3wt) (Hollywood and Hurst, 1993) , compared to the sequence present in plasmid pE2P.Pp.CAT (FP3mod) and to the sequence of the footprint C (FPC) of the oestrogen-dependent enhancer found in the ®rst intron of human ERBB2 (Bates and Hurst, 1997a) . The boxed part represents the`core binding sequence', as de®ned by methylation interference. (b) EMSA analysis of nuclear extracts from ZR75.1 cells, with probes representing the FP3wt (lanes a-i, q-s) and the FP3mod (lanes j-p, t-v). Competitions were carried out with a 30-fold excess of cold oligonucleotide, unless otherwise speci®ed: w=FP3wt; m=FP3mod; ns=non-speci®c DNA. Lanes q-v: complexes formed with either probe were supershifted with a preimmune IgG (P) or with AP-2 speci®c antibodies (A). Lanes a, b: in vitro translated hrAP2-a protein and the relative supershift. The asterisk indicates a non-speci®c band, while the arrows indicate the speci®c AP2 band (SC) and the supershifted complex (SS). medium and the nuclear content analysed. The level of AP-2, as measured by immunoblotting, is reduced in cells grown in the presence of oestrogen, and this correlates with the expression of the endogenous ErbB2 protein, measured on the same lysates (Figure 4) . The AP-2 antiserum used in this experiment was raised against an epitope in the C-terminal domain of the hAP-2a protein. However, using in vitro translated proteins, we found variable cross-reactivity with the other human isoforms (data not shown).
The DNA binding activity of AP-2 was then examined by EMSA, using the FP3wt probe. Surprisingly, this experiment showed that the complex formed by nuclear extracts of cells grown in oestrogenic conditions is not quantitatively less than that of cells with no oestrogens (Figure 5 , compare CM with Tam and SM with E2). This pattern was consistently observed also in dierent experimental conditions, such as higher or lower protein/DNA ratio in EMSA (data not shown), therefore we conclude that factors, other than oestrogen, dierentially present in CM vs SM media, regulate the DNA binding activity of AP-2, while oestrogens and antioestrogens do not, despite their eect on immunoblotting-measurable AP-2 protein level.
Since it was previously observed that ERBB2 promoter is strikingly up-regulated in con¯uent cells , we examined by EMSA the nuclear extracts from ZR75.1 cells grown at dierent degrees of con¯uence in both CM and SM media. As shown in Figure 6a , the FP3 complex shows a minimum at day 5 and is strongly increased starting from day 7 in CM. In SM, the minimum is at day 7 and the peak at days 13 ± 17. Immunoblotting analysis of the same nuclear extracts (Figure 6b) showed that, while at the ®nal points (days 7 ± 10 in SM, days 17 in SM) high AP-2 expression levels correlate with high DNA binding activity, at earlier time points there is no concordance between expression and binding (e.g. day 4 in CM, day 3 in SM). Alternatively cells were grown in oestrogen-deprived medium (SM) for 3 days and then treated or not with 10 mM 17b-oestradiol in SM for further 1 day (lanes d, f) or 3 days (lanes c, e). Upper panel: 60 mg of total protein extracts were separated on a 8% SDS ± PAGE gel, blotted onto a PVDF membrane and probed with the anti-ErbB2 speci®c antibody 21N. Lower panel: proteins were separated on a 12% polyacrylamide gel and probed with AP-2 speci®c antibody. The blots were previously stained with Ponceau Red to check for uniform loading and transfer Figure 5 Regulation of AP-2 binding activity by culture conditions. EMSA analysis of nuclear extracts from ZR75.1 cells with the FP3wt oligonucleotide probe. Cells were grown for 3 days in oestrogenic or non-oestrogenic conditions and then treated with 4-OH-tamoxifen or 17b-oestradiol for 3 days, as described in the legend to Figure 4 . For each nuclear extract, three lanes are run: the total binding (T) and the competition with a 30-fold excess of the cold FP3wt oligo (sc) or with non-speci®c DNA (nsc). SC: speci®c complex. *aspeci®c complex AP-2 and ERBB2 repression by oestrogen V Perissi et al
These experiments reveal that both AP-2 expression level and DNA binding ability are widely regulated by oestrogen and other factors. Unknown factors present in SM vs CM media, as well as cell con¯uence, regulate the total AP-2 amount together with its DNA binding activity, as measurable by EMSA. Oestrogen and antioestrogen regulate AP-2 level without apparently aecting its DNA binding activity at the ERBB2 promoter. Presently available reagents did not permit to address the question of which AP-2 isoform was prevalent in the dierent experimental conditions.
Constitutive expression of individual AP-2 proteins shows dierent eects on oestrogenic repression
Finally, we asked whether constitutive expression of AP-2 could modify oestrogenic regulation of the ERBB2 promoter. AP-2a, AP-2b and AP-2g expression vectors driven by the RSV promoter, as well as the void pSP.RSV.NN vector, were co-transfected, together with the pE2P.Pp.CAT reporter and the ER expression vector pHEG0, in ZR75.1 cells and the eect of oestrogen measured in CAT assay. Parallel transfections using the pA2B.CAT reporter, which carries three copies of the hMTIIa AP-2 element upstream from the E1b TATA box (Williams and Tijan, 1991) , were done to prove that transcriptionally competent AP-2 proteins were expressed. As shown in Figure 7b each of the three AP-2 vectors induced a 5 ± 6-fold increase in pA2B.CAT transcription.
AP-2a, AP-2b and AP-2g showed dierent eects on pE2P.Pp.CAT transcription (Figure 7a ). In contrast to what was seen on pA2B.CAT, AP-2b, AP-2g and, to a lesser extent, AP-2a repressed pE2P.Pp.CAT basal transcription. Notably, in the presence of AP-2b and AP-2g, pE2P.Pp.CAT repression by oestrogen was abrogated, whereas it was unchanged by AP-2a.
pA2B.CAT activity was increased by oestrogen in the presence of AP-2b or AP-2g, as well as in the control (a 3 ± 4-fold stimulation was observed on plasmid pB.CAT that contains the sole E1b TATA element (data not shown)), while it was repressed with AP-2a (Figure 7b ).
These results demonstrate that constitutive expression of two isoforms of AP-2 abrogate the estrogenic repression of ERBB2 promoter, con®rming the role of AP-2 in this transcriptional response. Furthermore, activated ER apparently extinguishes AP-2a, but not AP-2b or AP-2g, transactivating properties.
Since AP-2 had variable inhibitory eects on pE2P.Pp.CAT while activating pA2B.CAT, these data indicate that the FP3 site is not functionally equivalent to the triple AP-2 element in pA2B.CAT.
Discussion
In the present work, we con®rm that the 218 bp region upstream from the major transcriptional start site of the human ERBB2 gene promoter is repressed by oestrogen-activated ER in breast cancer cells and show that deletion or mutation of a distal sequence binding the AP-2 transcription factors completely abrogates oestrogen response.
Repression of both the human ERBB2 and rat NEU promoters linked to a CAT gene by oestrogenactivated ER was reported by other authors (Russel and Hung, 1992) . The rat NEU promoter is highly homologous to the human one, except that it lacks a TATA box and has a GTG element inserted at 76-bp 5' from the position where the TATA is located in the human (White and Hung, 1992) . The oestrogensensitive AP-2 site is not conserved in the rat NEU promoter and, in fact, the oestrogen-responsive region was localized to a more proximal fragment, capable of conferring oestrogenic repression to a basal TK promoter (Russel and Hung, 1992) . It may be interesting to note that the 5' end of the rat fragment also contains the 5'-CAGG sequence that characterizes the FP3 and FPC AP-2 sites.
Since a 410 bp portion of a ®rst intron enhancer confers oestrogen-dependent regulation to the ERBB2 promoter without the need of ER co-transfection, it was concluded that it represents the main site of oestrogen-dependent regulation of the human ERBB2 gene in vivo (Bates and Hurst, 1997a) . However, there is much evidence to prove that promoter sequences do play a role in the oestrogenic repression of ERBB2. First, a 1.2 kbp human ERBB2 promoter-CAT construct, stably integrated in T47.D cells, is repressed by oestrogen without the need of ER cotransfection . Second, a reproducible 15 ± 20% reduction of our reporter construct by endogenous ER is observed in ZR75.1 cells. Finally, both promoter FP3 and intronic enhancer FPC sequences bind AP-2 with equivalent anity and speci®city, suggesting that they are coregulated in vivo. Thus, juxtaposition of both enhancer and promoter, as in the natural context or in the reporter constructs described (Bates and Hurst, The conserved sequence 5'-CTGCAGG-3' in both FP3 and FPC, which represents the core binding sequence identi®ed by methylation protection experiments in FP3 (Hollywood and Hurst, 1993) , is also found in elements of E-cadherin and keratin gene promoters, reported to function through AP-2 factors (Hennig et al., 1996; Leask et al., 1991) . However, we failed to observe competition to either FP3 or FPC by an E-cadherin`E-pal' oligonucleotide (data not shown). In addition, mutations in the central nucleotides of FP3 do not aect binding, while mutations in the¯anking nucleotides abrogate binding. It could be hypothesized that the central part of the sequence, conserved in ERBB2, E-cadherin and keratin genes, binds other unidenti®ed factors in dierent cell types.
Even though apparent anities of ZR75.1 nuclear factors for either AP-2 or FP-3 oligonucleotides were similar, it is clear that, in its natural context, the FP3 sequence is not functionally equivalent to the canonical AP-2 element in plasmid pAB2.CAT. The endogenous AP-2 in ZR75.1 cells is sucient to transactivate the ERBB2 promoter but not the pA2B.CAT construct and transfecting any AP-2 strongly increases transcription of the latter, while variably inhibiting the former. One interesting possibility is that other factors may bind FP3 in co-operation with AP-2, increasing its anity for FP3. An example of this is given by the Agelatinase gene promoter, where an AP-2/YB-1 heterodimer binds to an element closely resembling FP3 (Mertens et al., 1998) .
We have not found de®nitive evidence on how oestrogen regulates AP-2 activity. Since the oestrogenic regulation of ERBB2 is slow and possibly requires protein synthesis , direct regulation of AP-2 expression seems a straightforward hypothesis. The discrepancy we have observed between immunoblotting and EMSA results may be only apparent. In fact, immunoblotting data refer to an overall level of AP-2 but, since the antibody used here shows dierent anity for AP-2a, AP-2b and AP-2g proteins, changes in their relative level may not be detected. In addition, due to the fact that in vitro translated hrAP-2a, AP-2b and AP-2g proteins heterodimerize (Bosher et al., 1996) and bind to the FP3 probe with comparable anity (not shown) it is also impossible to know which of the AP-2 factors is bound to the FP3 element by EMSA, even if isoformspeci®c antibodies were used.
Dierential expression of AP-2a, AP-2b and AP-2g proteins following oestrogen treatment may thus explain immunoblotting results, together with the unchanged DNA binding activity. Interestingly, we have recently veri®ed by RT±PCR that oestrogen and other factors dierentially aect AP-2a and AP-2g mRNA levels (Cottone, Pia and De Bortoli, in preparation) . Some recent evidence of AP-2 differential regulation in normal development and in cancer was also provided (Bisgrove and Godbout, 1999; Turner et al., 1998) .
Individual AP-2 proteins, alone or in conjunction with other factors, may interact with dierent sets of coactivators or corepressors, leading to stronger or weaker activation, or even repression of gene transcription (Hennig et al., 1996; Bisgrove and Godbout, 1999) .
The data obtained by the transient transfection experiments suggest that ER may interfere with AP-2a transactivation: oestrogen treatment represses both the ERBB2 promoter and the pAB2.CAT plasmid, in the presence of added AP-2a, but not when the other isoforms are transfected. This kind of repression suggests that ER and AP-2a compete for limiting coactivators. Recently, factors interacting with AP-2 and functioning as coactivators, also rescuing the autorepression showed by AP-2 in some experimental models (Kannan et al., 1994) , were identi®ed. One of these proteins is the PC4 coactivator , while a second protein is the transcription factor modifying enzyme PARP . It is interesting to note that the latter has been recently found to interact with members of the nuclear receptor family (Miyamoto et al., 1999) . It would be very interesting to determine if AP-2 transfection could inhibit transcriptional activity of ER or some other member of the nuclear receptor family.
An increase of AP-2 activity is typically observed during retinoic acid-induced dierentiation (OuladAbdelghani et al., 1996) . Indeed, AP-2 proteins regulate a number of genes related to epithelial cell dierentiation, like p21 waf/cip (Zeng et al., 1997) , Ecadherin (Hennig et al., 1996) , MXI1 (Benson et al., 1999) and ER-a itself (de Coninck et al., 1995) and AP-2 knock-out mice show several dierentiation defects in tissues of neuroectodermal origin and in kidney (Zhang et al., 1996; Schorle et al., 1996; Moser et al., 1997) . On the contrary, the action of oestrogen on mammary cells is mitogenic. Thus, it is not unlikely that the oestrogen receptor and AP-2 may interact at dierent levels, both regulating their reciprocal expression and by competing with common transcriptional co-activators, as results presented here suggest.
This work has disclosed an interesting and previously unidenti®ed relationship between steroid receptors and AP-2, which could also indicate new methods for controlling the expression of speci®c genes in cancer.
Materials and methods

Cell cultures
ZR75.1 and SKBR.3 human breast cancer cells were grown in a complete medium (CM) consisting of Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS). For oestrogen treatment, a`stripped' medium (SM) devoid of oestrogenic activity was used, composed by phenol red-free DMEM supplemented with 10% dextran-coated charcoal-treated FCS, as described (Dati et al., 1990 As a control for transfection eciency, 2 mg of plasmid pCH110 were co-transfected and the b-galactosidase activity measured by standard protocol. For deletant studies, cells were transfected with 20 mg of the CAT reporter vector and 2 mg of the ER expression vector pHEG0 or with the related empty vector pSG5. For AP-2 functional studies, 14 mg of the CAT reporter vector, 10 mg of AP-2 expression vectors (or empty vector) and 2 mg of pHEG0 were used.
The lysis of the cellular pellets and the CAT assay of the extracts obtained were performed as previously described . Protein concentration in the extracts was determined by the BCA protein assay (Sigma). CAT activity was expressed as c.p.m. acetylated form / total c.p.m. * 100 * mg 71 * h
71
. In alternative, the TLC was quantitated by PhosphorImager analysis and relative arbitrary units substituted for c.p.m.
Plasmids and plasmid construction
The pE2P.Pp.CAT construct containing the most proximal 218 bp of the ERBB2 promoter was previously described . pDtha.CAT was derived from pE2P.Pp.CAT by deleting the region between two ThaI restriction sites at 7274 and 7356. p(7224). CAT, p(7273) . CAT and p(7370) .CAT were constructed by PCR, using pE2P.Pp.CAT as template and cloned into pBLCAT3 between HindIII and BamHI cloning sites. Reverse primer was the sequence 7187 to 7178 and introduced an additional BamHI restriction site at the 3' end. The forward primers introduced a HindIII restriction site at the 5' end and corresponds to the sequences: 7224 to 7209 for p(7224).CAT; 7273 to 7260 for p(7273).CAT; 7370 to 7356 for p(7370). CAT. p(7413) .CAT was constructed by PCR ampli®cation of the promoter region from 7413 to 7178 using a genomic clone extended to the HindIII restriction site at 72205 as template . The forward primer corresponds to the sequence 7413 to 7398 and has an additional HindIII site at the 5' end.
pDPp.CAT was constructed from pE2P.Pp.CAT by deleting the four central bases of the PstI restriction site at 7397 by Klenow blunting. All the CAT reporter plasmids were veri®ed by sequencing on both strands.
pA2B.CAT and the related empty vector pB.CAT were kindly provided by Dr T Williams. pA2B.CAT contains three copies of the AP2 response element from hMTIIA upstream from the E1b minimal promoter (Williams and Tjian, 1991) . The AP2 expression vectors pSP(RSV)AP2a, pSP(RSV)AP2b and pSP(RSV)AP2g and the empty vector pSP(RSV)NN were a gift of Dr T Williams.
The hER expression vector pHEG0 was obtained from pHE0 (provided by P Chambon) by restoring 400 Gly by mutagenesis (Tora et al., 1989) .
Immunoblotting
Total protein extracts were obtained by on-plate lysis of the cells with a boiling buer containing 0.125 M Tris-HCl pH 6.8 and SDS 2.5%; the lysate was then homogenized by forcing through an insulin needle and cleared at 12 000 r.p.m. for 10 min. Proteins were measured with the BCA protein assay (Sigma) and 60 mg of protein were separated on 8% or 12% SDS ± PAGE and electroblotted to PVDF membranes (Millipore). Blots were stained with Ponceau Red to check for uniform loading and transfer. Polyclonal rabbit C-18 antiserum (Santa Cruz), directed against the C-terminal domain of human AP-2a, was used to detect AP-2, and the 21N polyclonal antiserum, a gift of Dr WE Gullick, for ErbB2. Speci®c proteins were visualized by ECL (Amersham).
Electrophoretic mobility shift assay 4 mg/reaction of nuclear extracts (Hoolywood and Hurst, 1993) , or 1 ml/reaction of in vitro-translated hAP2-a, hAP2-b or hAP2-g protein (TnT Promega) from pT7-SalAP2 clones (a gift of Dr HC Hurst) were incubated with 4 ng of 32 Plabeled probe and 1 mg of unrelated DNA (one part of polydIdC plus two parts of sonicated Calf Thymus DNA) in a 20 ml reaction volume containing: 10 mM Tris-HCl pH 7.9, 0.5 mM DTT, 100 mM NaCl, 0.5 mM EDTA, 10% glycerol and 0.05% NP40, plus the competing oligonucleotides, for 30 min at 48C. Samples were loaded onto a 6% acrylamide gel and electrophoresed in TBE 0.56 at 48C. Dried gels were exposed to X-ray ®lm overnight at 7808C.
Supershift was performed by adding 0.1 ml/reaction of the AP2 antibody C-18 to the binding reaction for 2 h at 48C. The following double-stranded oligonucleotides were used in EMSA assays: FP3wt, 5'-AGCTTGAGAACGGCTGCAGG-CAACCCAGGC; FP3mod, 5'-AGCTTGCATGCCTGCAG-GCAACCCAGGC; FPC, 5'-GTTGCAGGTACTGC-AGGGCATAG; FP3cm, 5'-AGCTTGAGAACGGCTTAA-GGCAACCCAGGCG; FP3lm, 5'-AGCTTGAGAACGTC-TGCAGTCAACCCAGGCG (bases diering from the wt sequence are underlined).
The AP2 consensus oligonucleotide 5'-GATCGAACT-GACCGCCCGCGGCCCGT-3' was purchased from Promega. Annealing between complementary single-strand oligonucleotides was performed in 50 mM Tris-HCl pH 7.6, 10 mM MgCl 2 , 5 mM DTT and 0.1 mM EDTA by gradual cooling (18C/min) from 958C.
Probes were end-labeled by ®lling the 3'-recessed ends with MMLV-RT (Promega) and a 32 P-dCTP (3000 Ci/mmol). Alternatively, the reverse complementary strand was synthetized copying the forward single-strand oligonucleotide from the octameric primer at the 3' end (5'-CGCCTGGG-3') with the Klenow enzyme, in the presence of [a-32 P]dCTP.
